.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Citi
AstraZeneca
McKinsey
Fuji
Merck
Cipla
Cerilliant
Chinese Patent Office
US Department of Justice

Generated: December 12, 2017

DrugPatentWatch Database Preview

Alvogen Company Profile

« Back to Dashboard

What is the competitive landscape for ALVOGEN, and what generic alternatives to ALVOGEN drugs are available?

ALVOGEN has forty-four approved drugs.

There is one US patent protecting ALVOGEN drugs.

There is one patent family member on ALVOGEN drugs in one country and eighty-two supplementary protection certificates in twelve countries.

Summary for Alvogen

International Patents:1
US Patents:1
Tradenames:37
Ingredients:34
NDAs:44
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Alvogen MaltaFELBAMATEfelbamateTABLET;ORAL204595-002Jan 11, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
AlvogenFORFIVO XLbupropion hydrochlorideTABLET, EXTENDED RELEASE;ORAL022497-001Nov 10, 2011RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Alvogen MaltaMACRODANTINnitrofurantoin, macrocrystallineCAPSULE;ORAL016620-001Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Alvogen MaltaDEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATEamphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateTABLET;ORAL207388-006Jul 28, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Alvogen MaltaOXYCODONE AND ACETAMINOPHENacetaminophen; oxycodone hydrochlorideTABLET;ORAL202677-003Mar 8, 2016AARXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Alvogen MaltaPYRIDOSTIGMINE BROMIDEpyridostigmine bromideTABLET, EXTENDED RELEASE;ORAL204737-001Jun 26, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
AlvogenOFLOXACINofloxacinSOLUTION/DROPS;OTIC090395-001Aug 11, 2009ATRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Alvogen MaltaDEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATEamphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfateTABLET;ORAL207388-004Jul 28, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Alvogen MaltaRIVASTIGMINErivastigmineFILM, EXTENDED RELEASE;TRANSDERMAL204403-003Aug 31, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Alvogen MaltaDISULFIRAM disulfiramTABLET;ORAL091681-001Aug 8, 2013ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Alvogen

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alvogen MaltaTENORETIC 50atenolol; chlorthalidoneTABLET;ORAL018760-002Jun 8, 1984► Subscribe► Subscribe
Alvogen MaltaTENORETIC 50atenolol; chlorthalidoneTABLET;ORAL018760-002Jun 8, 1984► Subscribe► Subscribe
Alvogen MaltaMACROBIDnitrofurantoin; nitrofurantoin, macrocrystallineCAPSULE;ORAL020064-001Dec 24, 1991► Subscribe► Subscribe
Alvogen MaltaTENORMINatenololTABLET;ORAL018240-004Apr 9, 1990► Subscribe► Subscribe
Alvogen MaltaZESTRILlisinoprilTABLET;ORAL019777-001May 19, 1988► Subscribe► Subscribe
Alvogen MaltaZESTRILlisinoprilTABLET;ORAL019777-002May 19, 1988► Subscribe► Subscribe
Alvogen MaltaTENORETIC 100atenolol; chlorthalidoneTABLET;ORAL018760-001Jun 8, 1984► Subscribe► Subscribe
Alvogen MaltaZESTRILlisinoprilTABLET;ORAL019777-005Apr 29, 1993► Subscribe► Subscribe
Alvogen MaltaZESTORETIChydrochlorothiazide; lisinoprilTABLET;ORAL019888-002Jul 20, 1989► Subscribe► Subscribe
Alvogen MaltaNAPRELANnaproxen sodiumTABLET, EXTENDED RELEASE;ORAL020353-002Jan 5, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ALVOGEN drugs

Drugname Dosage Strength Tradename Submissiondate
bupropion hydrochlorideExtended-release Tablets450 mgFORFIVO XL2/28/2013

Non-Orange Book Patents for Alvogen

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,703,191Controlled-release pharmaceutical tablets► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Alvogen Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2008038155► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Alvogen Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
90064-1Sweden► SubscribePRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
13/044Ireland► SubscribePRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
14/058Ireland► SubscribePRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516
C0021Belgium► SubscribePRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION NO/DATE: CH 54393 19971223
C/GB11/015United Kingdom► SubscribePRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
C/GB01/045United Kingdom► SubscribePRODUCT NAME: NATEGLINIDE OR SALTS THEREOF; REGISTERED: CH 55401 20000928; CH 55402 20000928; UK EU/1/01/174/001 20010403; UK EU/1/01/174/002 20010403; UK EU/1/01/174/003 20010403; UK EU/1/01/174/004 20010403; UK EU/1/01/174/005 20010403; UK EU/1/01/174/006 20010403; UK EU/1/01/174/019 20010403; UK EU/1/01/174/020 20010403; UK EU/1/01/174/021 20010403; UK EU/1/01/174/013 20010403; UK EU/1/01/174/014 20010403; UK EU/1/01/174/015 20010403; UK EU/1/01/174/016 20010403; UK EU/1/01/174/017 20010403; UK EU/1/01/174/018 20010403; UK EU/1/01/174/007 20010403; UK EU/1/01/174/008 20010403; UK EU/1/01/174/009 20010403; UK EU/1/01/174/010 20010403; UK EU/1/01/174/011 20010403; UK EU/1/01/174/012 2001040
90020-1Sweden► SubscribePRODUCT NAME: SACUBITRIL AND VALSARTAN, AS SACUBITRIL VALSARTAN SODIUM SALT COMPLEX, I.E. TRISODIUM 3-((1S,3R)-1-BIPHENYL-4-YLMETHYL-3- ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONATE-(S)-3-METHYL-2- (PENTANOYL2-(TETRAZOL-5-YLATE)BIPHENYL-4- YLMETHYLAMINO)BUTYRATE HEMIPENTAHYDRATE; REG. NO/DATE: EU/1/15/1058 20151123
2013 00053Denmark► SubscribePRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Cerilliant
Medtronic
McKesson
Harvard Business School
US Army
Colorcon
Deloitte
Argus Health
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot